Monitor for longer-term clinical data from REVEAL Phase 1/2 expected later this quarter, which will be a more significant catalyst. ASGCT presentation (May 11-15) could drive near-term upside.
Price Chart
Executive Summary
Taysha Gene Therapies announced positive preclinical in vitro data for TSHA-102, showing scAAV9 enables ~30-fold higher MeCP2 expression vs. ssAAV9 and miniMeCP2 is functionally comparable to full-length MeCP2, supporting its Rett syndrome gene therapy design. Data will be presented at ASGCT Annual Meeting (May 11-15, 2026), with longer-term clinical data from REVEAL Phase 1/2 expected later this quarter.
Key Facts
- scAAV9 enabled ~30-fold higher MeCP2 expression compared to ssAAV9 in neuronal cells
- MiniMeCP2 protein demonstrated functional comparability to full-length MeCP2 across molecular and biochemical assays
- Data support translational potential of TSHA-102's construct design for lumbar IT administration
- Longer-term safety and efficacy data from Part A REVEAL Phase 1/2 expected later this quarter
Financial Impact
Preclinical data validation; no financial impact disclosed.
Risk Factors
- Clinical trial risks: efficacy/safety data may not replicate preclinical findings
- Regulatory risks: FDA approval uncertain
- Funding risk: clinical-stage biotech may require additional capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282099 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Press Release | $6.41 $5.16 | ▼ −19.44% | ▼ −17.54% | $4.66 (−27.17%) |
Jun 25, 2026 14w ago | 8-K | $6.34 $5.83 | ▼ −8.04% | ▼ −9.30% | $4.66 (−26.42%) |
Jun 25, 2026 14w ago | 424B5 | $6.34 $5.83 | ▲ +8.04% | ▲ +9.30% | $4.66 (+26.42%) |
Jun 25, 2026 14w ago | Press Release | $6.21 $5.83 | ▲ +6.12% | ▲ +6.65% | $4.66 (+24.88%) |
Jun 5, 2026 17w ago | Press Release | $5.50 $6.38 | ▲ +16.00% | ▲ +14.14% | $4.66 (−15.18%) |
May 6, 2026 21w ago | 8-K | $6.98 $5.55 | ▼ −20.49% | ▼ −23.27% | $4.66 (−33.17%) |
May 6, 2026 21w ago | Press Release | $6.98 $5.55 | ▼ −20.49% | ▼ −23.27% | $4.66 (−33.17%) |
Apr 29, 2026 22w ago | Press Release | $6.27 $5.75 | ▼ −8.29% | ▼ −13.75% | $4.66 (−25.60%) |
Apr 27, 2026 22w ago | Press Release | $6.30 $5.59 | ▼ −11.27% | ▼ −16.74% | $4.66 (−25.95%) |
Apr 22, 2026 23w ago | DEFA14A | $6.72 $5.19 | ▼ −22.84% | ▼ −26.01% | $4.66 (−30.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access